The protective mechanism of SIRT3 and potential therapy in acute kidney injury
The structure highlights the dual-agonist design: a GIP-based backbone (cyan/blue tones) with GLP-1 receptor-engaging modifications, and the C-20 fatty diacid chain extending from the acylated Lys20 that enables once-weekly dosing
Used alongside a healthy diet and regular exercise, semaglutide could help prevent thousands of future major cardiovascular events and give many people the chance at a longer and healthier life. Jack Turner, Deputy Director for Medicines Negotiation at NHS England, said: Cardiovascular disease is one of the leading causes of preventable death and avoidable health harm, but its also one of the areas with the greatest innovation in the form of new pharmaceuticals and healthtech that are enabling millions of people to live with and better manage their heart condition. This latest NHS deal for an innovative medicine will enable NHS patients in England to benefit from the latest application of the drug, semaglutide, that is already helping people as a treatment for obesity and type 2 diabetes, contributing the 10 Year Health Plan ambition to prevent and manage more long-term conditions, in a way that avoids the need for emergency care. Health Minister Sharon Hodgson said: Weight loss drugs are proving to be a game changer in tackling obesity
GLP-1 medications delay gastric emptying, meaning food stays in your stomach longer, and they act on brain appetite centres to increase satiety signals
